Combined treatment with L-OHP and statins markedly inhibited the activation of NF-κB and Akt, expression of survivin, XIAP, Bcl-xL, and Bcl-2, and elevated JNK activation, expression of p53 and PUMA in KRAS-mutated colorectal cancer cells. This evidence concerns the gene BCL2 and colorectal cancer.